Detailed information for compound 307505
Basic information
Technical information
- TDR Targets ID: 307505
- Name: (2S)-N-[(2S,3S)-4-[[(2S)-1-amino-1-oxo-3-(4-p henylphenyl)propan-2-yl]amino]-3-hydroxy-1-ph enylbutan-2-yl]-2-[3-(1H-indol-3-yl)propanoyl amino]-3-methylbutanamide
- MW: 673.843 | Formula: C41H47N5O4
-
H donors: 6
H acceptors: 4
LogP: 5.8
Rotable bonds: 19
Rule of 5 violations (Lipinski): 3 - SMILES: O=C(N[C@H](C(=O)N[C@H]([C@H](CN[C@H](C(=O)N)Cc1ccc(cc1)c1ccccc1)O)Cc1ccccc1)C(C)C)CCc1c[nH]c2c1cccc2
- InChi: 1S/C41H47N5O4/c1-27(2)39(46-38(48)22-21-32-25-43-34-16-10-9-15-33(32)34)41(50)45-35(23-28-11-5-3-6-12-28)37(47)26-44-36(40(42)49)24-29-17-19-31(20-18-29)30-13-7-4-8-14-30/h3-20,25,27,35-37,39,43-44,47H,21-24,26H2,1-2H3,(H2,42,49)(H,45,50)(H,46,48)/t35-,36-,37-,39-/m0/s1
- InChiKey: RJCATVYOHCZSIZ-JEZWYNFKSA-N
Network
Hover on a compound node to display the structore
Synonyms
- (2S)-N-[(1S,2S)-3-[[(1S)-2-amino-2-oxo-1-[(4-phenylphenyl)methyl]ethyl]amino]-1-benzyl-2-hydroxy-propyl]-2-[3-(1H-indol-3-yl)propanoylamino]-3-methyl-butanamide
- (2S)-N-[(1S,2S)-3-[[(1S)-2-amino-2-oxo-1-[(4-phenylphenyl)methyl]ethyl]amino]-1-benzyl-2-hydroxypropyl]-2-[[3-(1H-indol-3-yl)-1-oxopropyl]amino]-3-methylbutanamide
- (2S)-N-[(2S,3S)-4-[[(2S)-1-azanyl-1-oxo-3-(4-phenylphenyl)propan-2-yl]amino]-3-hydroxy-1-phenyl-butan-2-yl]-2-[3-(1H-indol-3-yl)propanoylamino]-3-methyl-butanamide
- (2S)-N-[(1S,2S)-3-[[(1S)-2-amino-2-keto-1-(4-phenylbenzyl)ethyl]amino]-1-benzyl-2-hydroxy-propyl]-2-[3-(1H-indol-3-yl)propanoylamino]-3-methyl-butyramide
- (2S)-N-[(1S,2S)-3-[[(1S)-2-amino-2-oxo-1-[(4-phenylphenyl)methyl]ethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[3-(1H-indol-3-yl)propanoylamino]-3-methyl-butanamide
- (2S)-N-[(1S,2S)-3-[[(1S)-2-amino-2-oxo-1-[(4-phenylphenyl)methyl]ethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[[3-(1H-indol-3-yl)-1-oxopropyl]amino]-3-methylbutanamide
- (2S)-N-[(1S,2S)-3-[[(1S)-2-amino-2-keto-1-(4-phenylbenzyl)ethyl]amino]-1-(benzyl)-2-hydroxy-propyl]-2-[3-(1H-indol-3-yl)propanoylamino]-3-methyl-butyramide
- (2S)-N-[(2S,3S)-4-[[(2S)-1-amino-1-oxo-3-(4-phenylphenyl)propan-2-yl]amino]-3-hydroxy-1-phenyl-butan-2-yl]-2-[3-(1H-indol-3-yl)propanoylamino]-3-methyl-butanamide
- Hydroxylethylamine deriv. 23
Targets
Known targets for this compound
| Species | Target name | Source | Bibliographic reference |
|---|---|---|---|
| Plasmodium falciparum | plasmepsin I | Starlite/ChEMBL | References |
| Plasmodium falciparum | plasmepsin II | Starlite/ChEMBL | References |
| Homo sapiens | cathepsin D | Starlite/ChEMBL | References |
Predicted pathogen targets for this compound
By orthology
By sequence similarity to non orthologous known druggable targets
| Species | Potential target | Known druggable target | Length | Alignment span | Identity |
|---|---|---|---|---|---|
| Plasmodium vivax | aspartyl protease, putative | plasmepsin I | 452 aa | 368 aa | 26.1 % |
| Plasmodium falciparum | plasmepsin X | cathepsin D | 412 aa | 339 aa | 28.9 % |
Obtained from network model
Ranking Plot
Putative Targets List
| Species | Potential target | Raw | Global | Species |
|---|---|---|---|---|
| Leishmania major | C-8 sterol isomerase-like protein | 0.077 | 0.594 | 0.5 |
| Echinococcus granulosus | vesicular acetylcholine transporter | 0.1134 | 1 | 1 |
| Schistosoma mansoni | vesicular acetylcholine transporter | 0.1134 | 1 | 1 |
| Trypanosoma brucei | C-8 sterol isomerase, putative | 0.077 | 0.594 | 0.5 |
| Trypanosoma cruzi | C-8 sterol isomerase, putative | 0.077 | 0.594 | 0.5 |
| Onchocerca volvulus | Vesicular acetylcholine transporter homolog | 0.1134 | 1 | 0.5 |
| Toxoplasma gondii | aspartyl protease ASP1 | 0.0236 | 0 | 0.5 |
| Plasmodium falciparum | plasmepsin II | 0.0236 | 0 | 0.5 |
| Schistosoma mansoni | cathepsin D (A01 family) | 0.0351 | 0.128 | 0.128 |
| Plasmodium falciparum | plasmepsin IV | 0.0236 | 0 | 0.5 |
| Loa Loa (eye worm) | hypothetical protein | 0.0393 | 0.1752 | 0.1752 |
| Echinococcus multilocularis | vesicular acetylcholine transporter | 0.1134 | 1 | 1 |
| Plasmodium falciparum | plasmepsin I | 0.0236 | 0 | 0.5 |
| Plasmodium vivax | aspartyl proteinase, putative | 0.0236 | 0 | 0.5 |
| Trichomonas vaginalis | Clan AA, family A1, cathepsin D-like aspartic peptidase | 0.0236 | 0 | 0.5 |
| Loa Loa (eye worm) | vesicular acetylcholine transporter unc-17 | 0.1134 | 1 | 1 |
| Loa Loa (eye worm) | hypothetical protein | 0.077 | 0.594 | 0.594 |
| Schistosoma mansoni | cathepsin D (A01 family) | 0.0351 | 0.128 | 0.128 |
| Toxoplasma gondii | aspartyl proteinase (eimepsin), putative | 0.0236 | 0 | 0.5 |
| Plasmodium falciparum | plasmepsin VI | 0.0236 | 0 | 0.5 |
| Plasmodium vivax | plasmepsin IV, putative | 0.0236 | 0 | 0.5 |
Activities
| Activity type | Activity value | Assay description | Source | Reference |
|---|---|---|---|---|
| Inhibition (functional) | = 56 % | Percent inhibition of the compound against Plasmodium falciparum at 5 microM | ChEMBL. | 14695825 |
| Inhibition (functional) | = 56 % | Percent inhibition of the compound against Plasmodium falciparum at 5 microM | ChEMBL. | 14695825 |
| Ki (binding) | = 2.6 nM | Inhibitory activity against protease plasmepsin I (Plm I) of Plasmodium falciparum | ChEMBL. | 14695825 |
| Ki (binding) | = 2.6 nM | Inhibitory activity against protease plasmepsin I (Plm I) of Plasmodium falciparum | ChEMBL. | 14695825 |
| Ki (binding) | = 11 nM | Inhibitory activity against protease plasmepsin II (Plm II) of Plasmodium falciparum | ChEMBL. | 14695825 |
| Ki (binding) | = 11 nM | Inhibitory activity against protease plasmepsin II (Plm II) of Plasmodium falciparum | ChEMBL. | 14695825 |
| Ki (binding) | = 30 nM | Inhibitory activity of the compound against human cathepsin D | ChEMBL. | 14695825 |
| Ki (binding) | = 30 nM | Inhibitory activity of the compound against human cathepsin D | ChEMBL. | 14695825 |
Phenotypes
Whole-cell/tissue/organism interactions
We have no records of whole-cell/tissue assays done with this compound
What does this mean?
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
Annotated phenotypes:
We have no manually annotated phenotypes for this drug.
What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by
drugs, or by genetic manipulation of cells (e.g. gene knockouts or
knockdowns) is manually curated from the literature. These
descriptions help to describe the potential of the target for drug
development. If no information is available for this gene or if the
information is incomplete, this may mean that i) the papers
containing this information either appeared after the curation
effort for this organism was carried out or they were inadvertently
missed by curators; or that ii) the curation effort for this
organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
External resources for this compound
- ChEMBL: CHEMBL176845
- PubChem: 6539257
Bibliographic References
1 literature reference was collected for this gene.
If you have references for this compound, please enter them in a user comment (below) or Contact us.